August 29, 2024 07:42 AM EDT
R&D
Pharma

Mer­ck ends two Phase 3 stud­ies of Keytru­da, in­clud­ing an ear­ly-stage non-small cell lung can­cer tri­al

Kyle LaHucik

Senior Reporter

Mer­ck said Thurs­day morn­ing it is dis­con­tin­u­ing two Phase 3 tri­als of Keytru­da, the world’s top-sell­ing med­i­cine, af­ter in­de­pen­dent da­ta mon­i­tor­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

SEC probe of Il­lu­mi­na’s Grail deal tar­gets sales fore­casts, sources say

Post-Hoc: Big promis­es built Mod­er­na. They might al­so be its un­do­ing

FDA ap­proves sub­cu­ta­neous Ocre­vus, broad­en­ing ac­cess to Roche and Genen­tech block­buster

Af­ter a huge IPO and ac­qui­si­tion, Zymer­gen caps off bank­rupt­cy with $30M SEC penal­ty

Doug Williams re­turns with a ‘FIT’ bet on CAR-Ts; Bio­gen ap­points Mene Pan­ga­los to board

Cor­rect­ed: Roche’s Tecen­triq scores first US ap­proval for sub­cu­ta­neous PD-L1

A service from the Financial Times